Long-term effects of Org OD 14 on lipid metabolism in post-menopausal women

Kloosterboer, Helenius J.; Benedek-Jaszmann, L.J.; Kicovic, P.M.

doi:10.1016/0378-5122(90)90058-e

Cited by 32 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high density Iipoprotein 2 subfraction is regarded as the antiatherogenic fraction of high density lipoprotein-cholesterol (18). Furthermore, Klosterboer et al demonstrated that after treatment for 3 years, high density lipoprotein-cholesterol returned to pretreatment concentrations (17). However, in view of the important decrease of total high density lipoprotein, an increase of the coronary risk has to be postulated.…”

Section: Discussionmentioning

confidence: 98%

Postmenopausal Hormone Replacement Therapy with Tibolone Decreases Serum Lipoprotein(a)

Haenggi

Riesen²,

Birkhaeuser³

1993

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Lipoprotein(a) is a cholesterol-rich plasma lipoprotein consisting of LDL and apolipoprotein(a). Apolipoprotein(a) shows structural similarity with plasminogen and thus may interfere with thrombogenesis. Lipoprotein(a) has been shown to be a strong independent risk factor for coronary heart disease. So far no drug or diet is known to have prominent effects on the serum levels of lipoprotein(a).In the present study we found a highly significant decrease (in the order of 26%) of lipoprotein(a) in 28 women treated for 6 months with Tibolone, compared with an age-matched healthy control group.Tibolone is a synthetic steroid with gestagenic and weak androgenic and oestrogenic properties, which shows no stimulation of the endometrium. Tibolone also produced a decrease in HDL-cholesterol of 23% (p < 0.001), a decrease in apolipoprotein A-I of 14% (p < 0.001) and an increase in apolipoprotein B of 17% (p < 0.001), whereas the control group showed no significant changes in these quantities.Tibolone in a daily dose of 2.5 mg is at present the only complete postmenopausal hormone replacement therapy that shows a significant inhibiting influence on serum levels of lipoprotein(a). Its effect on lipoprotein(a) might counterbalance, at least to some extent, the theoretical adverse effect on the other lipoprotein risk factors.

show abstract

Section: Discussionmentioning

confidence: 98%

Postmenopausal Hormone Replacement Therapy with Tibolone Decreases Serum Lipoprotein(a)

Haenggi

Riesen²,

Birkhaeuser³

1993

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…In these studies, tibolone did not affect plasma LDL levels, but lowered both triglycerides and HDL. The decrease in HDL cholesterol levels appears to be transient as reported in a 36‐month monitoring [37], but in another study it failed to return to baseline after 2 years [38]. Studies performed in postmenopausal women with secondary hyperlipidemia (e.g.…”

Section: Discussionmentioning

confidence: 96%

The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia

Beer

Smelt

Vark

et al. 2002

Journal of Internal Medicine

View full text Add to dashboard Cite

Objective. To investigate the short-term effect of treatment with tibolone on plasma lipid and lipoprotein levels in postmenopausal women with type III hyperlipoproteinemia (HLP). Design and intervention. Patients were randomized to receive, in a double-blind cross-over fashion, a ®xed dose of tibolone, 2.5 mg once daily or placebo for 8 weeks. The two treatment periods were separated by a wash-out period of 6 weeks. At each visit body weight and blood pressure were determined. Before and after each treatment period, fasting venous blood samples were obtained from the patients for biochemical measurements. Setting. The Leiden University Medical Center. Subjects. Postmenopausal women with type III HLP (aged £65 years) were recruited from the Lipid Clinics of the Leiden University Medical Center, the Amsterdam Medical Center, the Utrecht Medical Center and the University Hospital Rotterdam. Five out of 25 women with type III HLP were eligible to be included in the study. Four of the ®ve included patients completed the study according to the protocol. One patient was excluded from blinded therapy because total cholesterol levels increased above 20 mmol L ±1 . Main outcome measures. A signi®cant reduction of plasma triglyceride, total cholesterol, VLDL cholesterol and VLDL triglyceride levels. Results. Plasma triglyceride and total cholesterol levels decreased from 6.82 3.58 to 2.45 1.36 mmol L ±1 and from 13.53 3.64 to 6.61 2.03 mmol L ±1 , respectively (both P < 0.05). The body mass index remained unchanged. The glycated haemoglobin percentage decreased signi®cantly from 5.8 to 5.3%. Treatment with tibolone resulted in a profound reduction in plasma apolipoprotein E, VLDL cholesterol and VLDL triglyceride levels (mean reductions of 66, 77 and 70%, respectively, P < 0.05). Conclusions. Tibolone is a valuable adjuvant to current therapy in postmenopausal women with type III HLP.

show abstract

“…Therefore, the elevating effect of transdermal estradiol with progesterone on HDL cholesterol in the women with a natural menopause might be weaker than in women with a surgical menopause 10 . Kloosterboer and co-workers demonstrated that, after treatment of women for 3 years with tibolone, HDL returned to pre-treatment levels 13 . Therefore, tibolone might be an alternative treatment of choice for HRT in the women with a natural menopause who have higher triglyceride levels.…”

Section: Discussionmentioning

confidence: 97%

Evaluation of the effect of tibolone and transdermal estradiol on triglyceride level in hypertriglyceridemic and normotriglyceridemic postmenopausal women

Dansuk

Ünal

Karageyim

et al. 2004

Gynecological Endocrinology

View full text Add to dashboard Cite

The objective of the present study was to quantify the magnitude of the association between the change in triglycerides and high-density lipoprotein (HDL) cholesterol levels with the use of tibolone and transdermal estrogen in postmenopausal women with hypertriglyceridemia and normotriglyceridemia. This prospective randomized study enrolled 140 postmenopausal women who had all been hysterectomized for almost a year or more. All subjects completed the 3-month follow-up. The 140 patients were divided into two groups: 70 were given transdermal 17beta-estradiol 0.05 mg/day, and 70 were given tibolone 2.5 mg/day. We compared the effects of tibolone and transdermal 17beta-estradiol on lipids and dimacteric symptoms of the patients. To evaluate the effects of tibolone and transdermal estrogens on triglycerides and HDL cholesterol in postmenopausal women with normotriglyceridemia and hypertriglyceridemia, the women were assigned to five groups according to triglyceride levels (0-100, 101-200, 201-300, 301-400 and > or = 401 mg/dl). We compared changes in the triglyceride and HDL cholesterol levels of each group after treatment. All 140 postmenopausal women completed the trial. No significant differences were found in baseline characteristics of the patients. The tibolone group showed a 22.6% decrease whereas the transdermal estrogen group had a 10.9% decrease in the mean triglyceride levels after 3 months of treatment. The mean decrease of triglyceride level with transdermal estradiol was approximately 11% in normotriglyceridemic and hypertriglyceridemic postmenopausal women. The mean decrease of triglyceride level was 17% in the normotriglyceridemic group and 22-30% in the hypertriglyceridemic groups with tibolone. While the mean HDL cholesterol level increased in the transdermal estrogen group (3.6%), it decreased in the tibolone group (9.3%). We found that tibolone decreased triglyceride levels much more than did transdermal estradiol. However, HDL cholesterol was decreased by tibolone and increased by transdermal estradiol. Tibolone had a more marked decreasing effect in postmenopausal women who had higher initial triglyceride levels. It is suggested that the beneficial effect of tibolone on the cardiovascular system might be greater in women with a high level of triglycerides.

show abstract

Long-term effects of Org OD 14 on lipid metabolism in post-menopausal women

Cited by 32 publications

References 17 publications

Postmenopausal Hormone Replacement Therapy with Tibolone Decreases Serum Lipoprotein(a)

Postmenopausal Hormone Replacement Therapy with Tibolone Decreases Serum Lipoprotein(a)

The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia

Evaluation of the effect of tibolone and transdermal estradiol on triglyceride level in hypertriglyceridemic and normotriglyceridemic postmenopausal women

Contact Info

Product

Resources

About